Background
==========

MKS is an autosomal recessive lethal condition characterized by occipital meningoencephalocele, polycystic kidneys, postaxial polydactyly and ductal plate malformation of the liver. Other frequently observed features can include the Dandy-Walker malformation (or other posterior fossa defects), dextrocardia, bowing of long bones, cleft lip and/or palate, *situs inversus*, low set ears, microphthalmia and iris coloboma. To date, mutations in nine MKS genes are reported as causative (Table [1](#T1){ref-type="table"}). The protein products of the nine MKS genes are all involved in the structure or function of either the ciliary basal body/transition zone or the axoneme of the primary cilia \[[@B1]-[@B5]\]. MKS is, therefore, the most severe inherited condition in a suite of similar conditions known as ciliopathies. Other conditions with ciliary involvement include Joubert syndrome, nephronophthisis, Bardet-Biedl syndrome, COACH syndrome and Senior-Løken syndrome. All of these syndromes are allelic at some loci, and share some phenotypic features. Primary cilia are ubiquitous organelles, which contribute to the multiorgan involvement in MKS and other ciliopathy phenotypes.

###### 

Genes mutated in Meckel-Gruber syndrome and related ciliopathies

  **Locus**   **Chromosome location**   **Gene name**   **Protein name**   **Other ciliopathies**              **Key reference**   **Common mutation in population**   **Reference**
  ----------- ------------------------- --------------- ------------------ ----------------------------------- ------------------- ----------------------------------- ---------------
  MKS1        17q22                     *MKS1*          MKS1               BBS13                               \[[@B1]\]           Finnish - c. 1408-35_1408-7del29    \[[@B1]\]
  MKS2        11q13.1                   *TMEM216*       TMEM216            JBTS2                               \[[@B2]\]           Ashkenazi - p.R73L                  \[[@B2]\]
              11q12.2                   *TMEM138*       TMEM138            JBTS16                              \[[@B3]\]                                               
  MKS3        8q22.1                    *TMEM67*        MECKELIN           JBTS6, NPHP11                       \[[@B4]\]           Pakistani - c. 1575 + 1 G \> A      \[[@B4]\]
  MKS4        12q21.32                  *CEP290*        CEP290             BBS14, JBTS5, LCA10, NPHP6, SLSN6   \[[@B5]\]                                               
  MKS5        16q12.2                   *RPGRIP1L*      RPGRIP1L           JBTS7, NPHP8                        \[[@B6]\]           Mixed European -p.T615P             \[[@B11]\]
  MKS6        4p15.33                   *CC2D2A*        CC2D2A             JBTS9                               \[[@B7]\]           Finnish - c. 1762 C \> T            \[[@B7]\]
  MKS7        3q22.1                    *NPHP3*         NPHP3              NPHP3                               \[[@B8]\]                                               
  MKS8        12q24.31                  *TCTN2*         TCTN2                                                  \[[@B9]\]                                               
  MKS9        17p11.2                   *B9D1*          B9D1                                                   \[[@B10]\]                                              

The nine genes reported to be mutated are listed, with key references indicated. Common founder mutations that have been identified previously are also indicated, with the ethnicity of the population studied and any relevant reference.

The genetic heterogeneity and phenotypic variability in MKS have hindered the development of an evidence-based strategy for genetic diagnosis. To facilitate the process of genetic diagnosis for families, the unequivocal identification of pathogenic variants, genotype-phenotype correlations and founder mutations in specific ethnic groups, therefore, has important clinical utility. To further define the allelic series of pathogenic mutations for seven of the nine known MKS genes, we have screened an unselected cohort of 87 separate individuals affected with MKS, from a total of 49 consanguineous families and 19 non-consanguineous. We report the identification of mutations in 26 consanguineous and 13 non-consanguineous families, and describe a total of 18 previously unreported mutations.

Methods
=======

Patient ascertainment and research ethics statement
---------------------------------------------------

Blood samples and/or DNA samples from fetuses diagnosed with Meckel-Gruber or Meckel-like syndrome, unaffected siblings and parents were collected from UK centers. Adults were recruited to research studies after informed consent, with adherence to the Declaration of Helsinki ethical principles for medical research involving human subjects. Studies had favorable ethical approval from Leeds (East) Local Research Ethics Committee (study title "Molecular genetic investigations of autosomal recessive conditions", REC reference number 08/H1306/85). DNA was extracted using QIAGEN (Crawley, West Sussex, UK) extraction kits following the manufacturer's protocol by the Yorkshire Regional Genetics Service (<http://www.leedsth.nhs.uk/sites/genetics/>). Other DNA samples were obtained from referring clinicians or collaborators.

Microsatellite genotyping and direct Sanger sequencing
------------------------------------------------------

DNA from affected individuals was genotyped for microsatellite markers that flanked seven of the nine known MKS genes (*MKS1*, *TMEM216*, *TMEM67/MKS3*, *RPGRIP1L*, *CC2D2A*, *CEP290* and *TMEM237*) at \<1 cM genetic distance (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). Markers were PCR amplified using standard protocols, with the forward primer 5′ end-labelled with FAM (Sigma-Aldrich Ltd., Gillingham, Dorset, UK). Samples were run on an ABI3100 sequencer with ROX-500 (Applied Biosystems, Inc. Carlsbad, CA, USA) size standard. In samples from singleton or multiplex affected individuals of consanguineous origin, two homozygous markers indicated putative linkage to a locus under investigation, prioritizing the gene for subsequent sequencing. In non-consanguineous multiplex families, two or more affected individuals sharing haplotypes for flanking markers indicated putative linkage to a locus. DNA samples from singleton non-consanguineous samples were screened for the seven MKS genes described above. If linkage analysis (when performed) did not specifically exclude the involvement of the *MKS1*, *MKS2*, *MKS3* and *MKS6* loci, patients were then sequenced for the *MKS1*, *TMEM216*, *TMEM67* and *CC2D2A* genes. PCR primers were designed using Primer3 software (<http://frodo.wi.mit.edu/primer3/>) covering all coding exons and flanking intronic regions (Additional file [2](#S2){ref-type="supplementary-material"}: Table S2). A total of 188 coding exons were amplified by standard PCR protocols. PCR products were then purified using Exo-SAP (USB) following the manufacturer's protocol. Bidirectional Sanger sequencing was performed using a "BigDyev3.0" sequencing kit (Applied Biosystems, Inc.) by standard protocols recommended by the manufacturer. Samples were run on a ABI3100 sequencer and analyzed using "SeqScape" and "Sequencing Analysis" software (both Applied Biosystems, Inc.).

Analysis of mutations
---------------------

The expected segregation of putative mutations was confirmed in families, whenever possible, and their absence was confirmed in databases of common benign variants (dbSNP <http://www.ncbi.nlm.nih.gov/projects/SNP/>, 1000 Genomes Project <http://www.1000genomes.org/> and <http://evs.gs.washington.edu/EVS/> as appropriate). The pathogenic potential of putative missense mutations was assessed by analysis with PolyPhen2 (<http://genetics.bwh.harvard.edu/pph2/>), or by manual comparison of CLUSTALX alignments of protein homologues to determine the phylogenetic conservation of mutated amino acid residues. We confirmed the absence of the mutant alleles in a panel of 96 DNA samples from ethnically-matched normal control individuals.

Results
=======

In this study we identified mutations in n = 38/68 (55.9%) families that were recruited to the study (Table [2](#T2){ref-type="table"}). Out of all families with identified mutations, 19 (50%) had changes in *TMEM67* (Figure [1](#F1){ref-type="fig"}a), which highlights the prevalence of *TMEM67* mutations as a major cause of MKS. The second most commonly mutated genes were *CEP290* and *MKS1* (each n = 5/68 families; 3.2%). Mutations in *CC2D2A* and *RPGRIP1L* each had mutations in n = 3/68 families (7.9%). *TMEM216*, *TMEM138* and *TMEM237* each had mutations in only one family (2.6% each), confirming that these were uncommon causes of the MKS phenotype.

###### 

Clinical data and sequencing results of consanguineous and non-consanguineous patients with MKS and MKS-like phenotypes

  **Sample**               **Mutation**         **Phenotype**                                                                                                         
  ------------------------ -------------------- --------------- --------------------------------- ------------------------------------- ---- ---- ---- ---- ---- ---- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Consanguineous**                                                                                                                                                  
  102 + 103 + 244 + 270    Pakistani            MKS1            c\. 1448_1451dupCAGG              MKS1 c. 1448_1451dupCAGG              \+   \+   \+        \+        Short neck, low set ears, bilateral talipes, syndactyly, micropenis, *situs inversus*, congenital heart defect inc. dextrocardia, short femurs and short spindle-shaped tibiae, deformed tongue
  264                      Jordanian            MKS1            c\. 1408-35_1408-6del30^*N*^      c.1408-35_1408-6del30^*N*^                                          diagnosed with MKS
  42 + 43                  Pakistani            TMEM138         c\. A287G p.H96R                  c\. A287G p.H96R                      \+   \+        \+              
  29A + 33A                Pakistani/Mirpuri    TMEM67          c\. 1575 + 1 G \> A               c\. 1575 + 1 G \> A                   \+   \+   \+   \+              
  70                       Pakistani/Mirpuri    *TMEM67*        c\. 1575 + 1 G \> A               c\. 1575 + 1 G \> A                        \+                  \+    
  76                       Pakistani/Mirpuri    *TMEM67*        c\. 1575 + 1 G \> A               c\. 1575 + 1 G \> A                   \+   \+                        
  77117                    Pakistani            *TMEM67*        c\. 1575 + 1 G \> A               c\. 1575 + 1 G \> A                                                 diagnosed with MKS
  51                       Pakistani/Mirpuri    *TMEM67*        c\. 870-2A \> G                   c\. 870-2A \> G                       \+                             
  73                       Pakistani/Mirpuri    *TMEM67*        c\. 870-2A \> G                   c\. 870-2A \> G                       \+   \+        \+              
  319                      British              *TMEM67*        c\. 1392 C \> T p.R441C           c\. 1392 C \> T p.R441C                    \+        \+             some dialation of pancreatic ducts, hydrocephalus, posterior fossa cyst
  347                      Pakistani            *TMEM67*        c\. 1392 C \> T p.R441C           c\. 1392 C \> T p.R441C                                             diagnosed with MKS
  67FB                     Pakistani            *TMEM67*        c\. 647delA, p.E216fsX221         c\. 647delA, p.E216fsX221             \+   \+        \+   \+         
  P95                      Pakistani            *TMEM67*        c\. 1127A \> C p.Q376P            c\. 1127A \> C p.Q376P                \+   \+        \+              
  125                      Omani                *TMEM67*        c\. 383_384delAC p.H128fsX140     c\. 383_384delAC p.H128fsX140         \+   \+   \+             \+    
  170                      Turkish              *TMEM67*        c\. 1674 + 1 G \> A^*N*^          c\. 1674 + 1 G \> A^*N*^                                            diagnosed with MKS
  205                      Chinese              *TMEM67*        c\. 1615 C \> T p.R549C^*N*^      c\. 1615 C \> T p.R549C^*N*^               \+        \+             hypoplastic cerebellum, small fourth ventricle with large cisterna magna, small defect in superior aspect of occipital bone
  C28                      Pakistani            *TMEM67*        c\. 274 G \> A p.G92R^*N*^        c\. 274 G \> A p.G92R^*N*^                                          MTS, coloboma, mental retardation
  39                       Pakistani/Mirpuri    *CEP290*        c\. 1429 C \> T p.R477X^*N*^      c\. 1429 C \> T p.R477X^*N*^               \+        \+              
  292                      Pakistani            *CEP290*        c\. 954delT p.S318fs16X^*N*^      c\. 954delT p.S318fs16X*N*            \+                             
  333                      Pakistani            *CEP290*        c\. 5744insT p.G1915FfsX1^*N*^    c\. 5744insT p.G1915FfsX1^*N*^        \+                             
  207                      Pakistani            *RPGRIP1L*      c\. 1945 C \> T p.R649X^*N*^      c\. 1945 C \> T p.R649X^*N*^          \+   \+   \+                  small cerebellum
  336                      Pakistani            *RPGRIP1L*      c\. 1945 C \> T p.R649X^*N*^      c\. 1945 C \> T p.R649X^*N*^                                        diagnosed with MKS
  158                      Pakistani            *CC2D2A*        c\. 3540delA p.R1180SfsX6^*N*^    c\. 3540delA p.R1180SfsX6^*N*^        \+   \+   \+   \+   \+        low set ears, pulmonary hypoplasia, intestinal malrotation, markedly enlarged pancreas- irregular ducts on histology, brain shows dilated fourth ventricle with small cerebellum, poorly developed pyramidal tracts and some possible dysplasia in the basal ganglia
  180                      Pakistani            *CC2D2A*        c\. 3540delA p.R1180SfsX6^*N*^    c\. 3540delA p.R1180SfsX6^*N*^        \+   \+   \+             \+    
  261                      Jordanian            *TMEM237*       c\. 1066_1067dupC p.Q356PfsX23    c\. 1066_1067dupC p.Q356PfsX23                                      meningomyelocele, developmental delay, cortical visual impairment
  178                      Pakistani/Mirpuri    *TMEM67*        c\. 1615 C \> T p.R549C^*N*^      not detected                                                        diagnosed with MKS
  16 + 17                  Pakistani            *CC2D2A*        c\. 685_687delGAA het p.E229del   not detected                               \+        \+              
  66 F1 + 66 F2            Pakistani            *CC2D2A*        c\. 685_687delGAA het p.E229del   not detected                          \+   \+   \+   \+             absent uterus, micrognathia, bilateral talipes, low set ears, wide spread eyes
  **Non-Consanguineous**                                                                                                                                              
  106                      British              *MKS1*          c\. 1408-35_1408-7del29           c\. 1408-35_1408-7del29               \+   \+   \+   \+              
  77172                    Finnish              *MKS1*          c\. 1408-35_1408-7del29           c\. 811delC p.H271fsX29^*N*^                                        diagnosed with MKS
  74699                    British              *MKS1*          c\. 1408-35_1408-7del29           c\. 1408-35_1408-7del29                                             diagnosed with MKS
  162 + 163                British              *TMEM216*       c\. 253 C \> T p.R85X^†^          c\. 253 C \> T p.R85X^†^              \+   \+   \+   \+   \+        facial dysmorphism, postural deformities of limbs, small perimembranous ventricular septal defect, intestinal malrotation
  176 + 177                British              *TMEM67*        c\. 1426 C \> T p.P476S^††^       c\. 2440--3 C \> A                    \+   \+   \+   \+             flexion deformity of elbows and wrists, low set ears
  186                      British              *TMEM67*        c\. 755 T \> C p.M252T            c\. 653 G \> T p.R208X†††             \+   \+                        
  302                      British              *TMEM67*        c.755 T \> C p.M252T              c.651 + 5 G \> A p.V217Vfs^*N*^            \+        \+        \+   agenesis of corpus callosum
  83527                    Norwegian-Indian     *TMEM67*        c\. 755 T \> C p.M252T            c\. 2882 C \> A p.S961Y^*N*^          \+   \+        \+              
  74406a + b                                    *TMEM67*        c\. 1351 C \> T p.R451X           c\. 2108 T \> A p.V673A                    \+        \+             mental retardation, retinal coloboma
  210 + 239                Dutch                *CEP290*        c\. 679_680delGA p.E227SfsX2      c\. 1984 C \> T p.Q662X                    \+        \+        \+   abnormal cerebellum, wide nasal bridge, extended abdomen*,* thoracic and abdominal *situs inversus*, intestinal rotation, small bladder, uterus duplex
  153 + 154                French               *CEP290*^*a*^   c\. 2251 C \> T p.R751X           c\. 4864insTdelCG p.R1622FfsX9^*N*^        \+                        
  166                      British              *RPGRIP1L*      c\. 1829A \> C p.H610P            c\. 721_724delAATG p.N241fsX25        \+   \+   \+             \+    
  128                      British              *CC2D2A*        c\. 3544 T \> C p.W1182R          c\. 3774_3774insT p.E1259fsX1                                       diagnosed with MKS
  36 + 36A                 Pakistani/Gujarati   *RPGRIP1L*      c\. 466 C \> T p.R156C\*^*N*^     not detected                          \+   \+                        
  111 + 112                Portuguese           *CEP290*        c\. 1451delA p.K484fsX8           not detected                          \+   \+   \+                   
  202                      British              *CC2D2A*        c\. 685_687delGAA p.E229del\*\*   not detected                          \+   \+                       craniofacial abnormalities related to oligohydramnios, bone-cartilage junctions showed disarray

CLP, cleft lip/palate; DPM, ductal plate malformation; DWM, Dandy-Walker malformation; OE, occipital encephalocele; PD, polydactyly; PK, polycystic kidneys; \* *in cis* with c. 3790 G \> A het p.D1264N, \*\* *in cis* with c. 3893 T \> A p.V1298D; ^†^ p.R85X allele was present in 2/10,266 European/African/American controls in the Exome Variant Server (EVS) database, ^††^ p.P476S allele present in 6/7,012 European/American controls (EVS), ^†††^ p.R208X allele present in 8/7,012 European/American controls (EVS). The remaining changes are excluded in about 10,000 European/African/American controls (EVS). ^*N*^ indicates a novel mutation that has not previously been reported. ^*a*^ indicates that affected siblings 153 + 154 are compound heterozygotes for *CEP290* mutations, but both also carry a third heterozygous putative pathogenic mutation in *TMEM216* c. 188 T \> G p.L63R.

![**Pie charts summarizing mutation analysis in MKS and MKS-like patients. a**) frequency of genes mutated in MKS and MKS-like phenotype; **b**) frequency of MKS genes mutations in consanguineous patients; **c**) common mutations in *MKS1*; **d**) common mutations in *TMEM67*; **e**) frequency of MKS genes mutations in non-consanguineous patients.](2046-2530-1-18-1){#F1}

In addition, six families were identified with a single heterozygous mutation in an MKS gene, but we were unable to identify a second pathogenic variant. *CC2D2A* p.E229del is probably a common variant, and it was detected as a single heterozygous variant in two families of Pakistani origin. In family 36 + 36A and family 202, two changes in the same gene were detected but were inherited *in cis* from the paternal line, so the pathogenic potential of these variants is unclear. We did not detect any other potential pathogenic changes in any of the seven MKS genes that we screened for these patients. Family 178 has the single heterozygous missense mutation p.R549C that is likely to be pathogenic because the same mutation is found in the homozygous state in family 205. This mutation may be a Chinese founder mutation (K. Szymanska, personal communication).

We identified homozygous mutations predicted to be pathogenic in 50% of consanguineous families (Figure [1](#F1){ref-type="fig"}b). Two families had mutations in *MKS1*. Family 264 had the homozygous *MKS1* mutation c. 1408-35_1408-6del30 (Figure [1](#F1){ref-type="fig"}c), which is almost identical to the "Finn major" Finnish founder mutation (c. 1408-35_1408-7del29) with one base-pair difference. Since family 264 is of Jordanian origin and, therefore, has a different genetic background from northern European patients with the "Finn major" mutation, this finding suggests a mutation hot spot in this intronic region of the *MKS1* gene. We identified three different homozygous mutations in *CEP290* in Pakistani families. Two of these were frameshift mutations with one nonsense, predicted to cause nonsense-mediated decay.

The majority of identified mutations were found in *TMEM67* (Figure [1](#F1){ref-type="fig"}b), comprising n = 14/47 (29.8%) families. Two splice-site mutations and one missense mutation were identified as recurrent in families and, therefore, probable founder mutations (Figure [1](#F1){ref-type="fig"}d). In patients of Pakistani ethnic origin, the two *TMEM67* splice-site mutations are c. 1546 + 1 G \> A and c. 870-2A \> G, previously reported as common mutations in *TMEM67*\[[@B6]\]. We identified the homozygous missense mutation p.R441C in two families (319 and 347), a mutation reported previously in the heterozygous state for patients with COACH syndrome \[[@B7]\]. A missense mutation affecting the same amino-acid residue, p.R441L, has also been reported previously in an MKS patient \[[@B8]\]. Since families 319 and 347 have different ethnic origins (British and Pakistani, respectively), this emphasizes the mutability of arginine residues and their importance to the function of the protein since the neighboring residue p.R440 is also mutated in MKS and MKS-associated ciliopathies \[[@B9]-[@B11]\].

We identified probable founder mutations in both *RPGRIP1L* and *CC2D2A* for families of Pakistani ethnic origin. The *RPGRIP1L* nonsense mutation c. 1945 C \> T p.R649X was observed in families 207 and 336, which are reported to be unrelated. The frameshift mutation in *CC2D2A* c. 3540delA p.R1180SfsX6 occurred in the unrelated families 158 and 180, with polydactyly noted as an obligatory feature in all affected individuals.

Two-thirds (n = 13/19) of non-consanguineous families had their causative mutations identified (Figure [1](#F1){ref-type="fig"}e), with the majority of mutations (n = 10/13) in the compound heterozygous state. The majority of identified mutations were found in the *TMEM67* gene, with mutations in *MKS1* and *CEP290* the next frequent. In our cohort, the "Finn major" mutation was found in all *MKS1-*mutated patients, either in the homozygous state for two patients (families 106 and 74,699 of British origin), and in one patient (family 77,172 of Finnish origin) as a compound heterozygous mutation *in trans* with the frameshift mutation p.H271*fs*X29. Overall, the *MKS1* "Finn major" mutation was the most frequent (Figure [1](#F1){ref-type="fig"}c). The heterozygous missense mutation p.M252T accounted for 30% of identified alleles in *TMEM67* in non-consanguineous patients. The previously reported common Finnish *CC2D2A* mutation is absent in our cohort \[[@B12]\], even though the *MKS1* "Finn major" Finnish mutation seems frequent. This suggests that the latter is more widespread throughout European populations, whereas the *CC2D2A* mutation seems to be less common outside Scandinavia.

Discussion
==========

There are previous reports of genotype-phenotype correlations in MKS \[[@B8],[@B9],[@B13]\]. We confirm some of these correlations with the available clinical data for our cohort of MKS patients. Occipital encephalocele and polycystic kidneys were almost obligatory features for all patients. Individuals with *TMEM67* mutations frequently had a diagnosis of ductal plate malformation in the liver (n = 10/19), but polydactyly was infrequent (n = 3/19) compared to *RPGRIP1L* and *CC2D2A* mutated individuals (n = 4/6; *P* \< 0.001, chi-squared test) The Dandy-Walker malformation (or a posterior fossa defect) was occasionally observed in patients with *TMEM67* mutations (n = 3/19). Retinal colobomata were only observed for *TMEM67*-mutated individuals (n = 2/19). Furthermore, *situs* or gut malrotation defects were never caused by *TMEM67* mutations (n = 0/19), in contrast to the occasional manifestation of these clinical features with *MKS1*, *TMEM216*, *CEP290* or *RPGRIP1L* mutations (n = 4/17; *P* \< 0.05, chi-squared test).

Mutation analysis in our MKS and MKS-associated ciliopathy cohort has allowed us to observe some common mutations that have arisen from probable founder effects, supported by the observation of common shared haplotypes in affected individuals (Additional file [3](#S3){ref-type="supplementary-material"}: Figure S1). These observations will allow initial prioritization of gene and exon screened in affected patients. Patients diagnosed with MKS, and that have additional features of ductal plate malformation and/or retinal coloboma, should be tested for *TMEM67* mutations since, in any case, MKS mutations are most frequent in this gene. In consanguineous families of Pakistani origin, the *TMEM67* splice-site mutations c. 1546 + 1 G \> A and c. 870-2A \> G should be prioritized. In addition, screening for missense mutations between amino acid residues 250 to 570 would detect a third (n = 10/29) of all of the *TMEM67* mutations in this cohort. It is likely that missense or nonsense mutations of conserved arginine residues in this region (for example, R441C, R451X and R549C), may be recurrent and could, therefore, be founder mutations in other population groups. In consanguineous Pakistani families, the probable founder mutations *RPGRIP1L* c. 1945 C \> T p.R649X and *CC2D2A* c. 3540delA p.R1180SfsX6 should also be prioritized. For families of northern European (including British) origin, without a known history of consanguinity, testing the *TMEM67* missense mutation p.M252T may be useful, but the most common mutation is the *MKS1* "Finn major" mutation. Our results demonstrate the broad phenotypic variability in MKS and the lack of clear genotype-phenotype correlations to guide diagnostic choices. Furthermore, some MKS mutations, such as the *TMEM67* p.R440Q missense mutation, are allelic for Joubert syndrome and other ciliopathies.

The molecular basis of the phenotypic variability in MKS may arise from oligogenic inheritance \[[@B14]\], where a third modifier allele modifies the phenotypic effect of two recessive alleles. It is interesting to note that many ciliopathy and ciliary-related proteins interact and are reported to create functional modules that are localized to discrete structural regions of the cilium, such as the transition zone \[[@B1]-[@B3],[@B5]\]. The effect of modifier alleles may be to abrogate interactions between components of a functional module, which may disrupt protein complexes or signaling pathways giving rise to the ciliopathy phenotype. We identified four different heterozygous changes in six patients, in the absence of a second detectable pathogenic mutation in the same gene or any other mutations in other MKS genes. These heterozygous alleles could be potential modifier alleles, but we have not exhaustively excluded the possibility that a second pathogenic mutation is a large deletion spanning exons and/or introns in the same MKS gene, which would not be detected with PCR amplification and direct sequencing alone. Although we have not assessed gene dosage in these genes by, for example, a multiplex ligation-dependent probe amplification strategy, we have seen no evidence of allele drop-out at the same or other known MKS loci following genome-wide SNP genotyping of consanguineous patients (individuals 178, 16 + 17 and 66 F1 + 66 F2). We have also not excluded the possibility that a second point mutation occurs deep within introns or regulatory elements of the same MKS gene. Interestingly, two affected siblings (153 + 154) were compound heterozygotes for *CEP290* mutations (Table [2](#T2){ref-type="table"}), but also carried a third heterozygous putative mutation c. 188 T \> G p.L63R in *TMEM216*. This was the only occurrence of possible triallelic inheritance in our cohort for the seven MKS genes that we screened, although the pathogenic potential of this third *TMEM216* allele remains unclear.

Conclusion
==========

In conclusion, our data provide further useful information about the mutational load in MKS patients from different ethnic backgrounds. With the ever-increasing power and affordability of genetic sequencing technologies, there is now the clear opportunity for the further rapid and robust identification of mutations in patients referred for a defined condition. As a prerequisite, there remains a pressing clinical need for the dissemination of mutations identified on a research basis, and the establishment of databases that provide detailed clinical phenotypes and allelic series for specific genes.
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**Table S2.** Primer sequences used for direct Sanger sequencing of MKS genes.
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###### Additional file 3

**Figure S1.** Haplotypes for common mutations in *TMEM67*, *CC2D2A* and *RPGRIP1L*. Putative shared common disease haplotypes (genotypes in bold) are shown for the indicated microsatellite markers on the left that flank the MKS genes *TMEM67*, *CC2D2A* and *RPGRIP1L*. The numerical identifier of each affected individual is shown underneath each haplotype (see Table [2](#T2){ref-type="table"} for further details).
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